Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder
- 2 March 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 39 (2) , 153-157
Abstract
Posttraumatic stress disorder (PTSD) is often a chronic, disabling illness for which antidepressant medications (ie, SSRI) are considered the primary psychopharmacological treatment. However, many patients remain refractory to antidepressants alone or in combination with psychotherapy. Safe and effective treatments for individuals with refractory PTSD are needed. This study aimed to examine ziprasidone augmentation of SSRI treatment of PTSD. This was a 2-phase study. In phase 1, subjects were treated with paroxetine or sertraline for 8 weeks. Individuals refractory to the SSRI treatment then entered into phase II of the study and were randomized, in a double-blind fashion, to 8 weeks of treatment with either ziprasidone or placebo. The primary outcome measure was change in Clinician Administered PTSD Scale total scores with the intent-to-treat sample. Secondary outcome measures included Positive and Negative Syndrome Scale scores, measures of depression and anxiety, and safety measures. No significant differences were observed on the Clinician Administered PTSD Scale, Positive and Negative Syndrome Scale, or other outcome measures between ziprasidone and placebo groups. No significant differences were observed for safety measures including metabolic profiles, extrapyramidal symptoms/movement disorder rating scales, nor study dropout. Although no significant differences were noted in efficacy or safety measures between ziprasidone and placebo in this pilot study, the small sample size prevents definitive conclusions.Keywords
This publication has 29 references indexed in Scilit:
- Primary Add-on of Ziprasidone in Sertraline Treatment of Posttraumatic Stress DisorderJournal of Clinical Psychopharmacology, 2010
- Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical TrialsCNS Drug Reviews, 2007
- Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind studyInternational Clinical Psychopharmacology, 2006
- Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic featuresInternational Journal of Neuropsychopharmacology, 2006
- Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptomsInternational Clinical Psychopharmacology, 2003
- Adjunctive Olanzapine for SSRI-Resistant Combat-Related PTSD: A Double-Blind, Placebo-Controlled StudyAmerican Journal of Psychiatry, 2002
- The measurement of disabilityInternational Clinical Psychopharmacology, 1996
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960